A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 16 Aug 2024
At a glance
- Drugs Talquetamab (Primary) ; Talquetamab (Primary) ; Recombinant human serum albumin
- Indications Multiple myeloma
- Focus Adverse reactions; First in man; Registrational
- Acronyms MonumenTAL-1
- Sponsors Janssen Research & Development; Janssen-Cilag
- 28 Jun 2024 Planned End Date changed from 30 Apr 2025 to 22 May 2025.
- 12 Dec 2023 Results (n=70; as of 17 Jan 2023) of an updated analysis including all patients from phase 1 and 2 MonumenTAL-1 trials who received 1 of the 2 recommended phase 2 doses of subcutaneous talquetamab and who were exposed to a TCR (prior CAR-T and BsAb) presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 According to a Janssen media release, results from this trial were featured in a poster presentation at the 2023 American Society of Hematology (ASH) Annual Meeting.